FDAsafety guidance72% confidence
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Bristol-Myers Squibb.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Immunotherapy
- Sub-indication
- General
Related signal: Nivolumab Phase III Trial for High Risk Stage II-IIIB Anal Cancer Initiated